Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200831 | 0.78 | HTR6 (0.60) | HTR6DRD2HTR2CHTR7HTR2B | |
| SCHEMBL4480373 | 0.78 | HTR6 (0.56) | HTR6ALDH1A1L3MBTL1DRD2HTR2C | |
| SCHEMBL28128683 | 0.76 | FFAR2 (0.56) | HTR6ALDH1A1HTR2ASLC6A2PTPN11 | |
| SCHEMBL5972123 | 0.73 | HTR6 (0.59) | HTR6ALDH1A1DRD2HTR2CHTR7 | |
| SCHEMBL4483917 | 0.72 | HTR6 (0.48) | HTR6DRD2HTR2CHTR7HTR2B | |
| SCHEMBL4494776 | 0.70 | HTR6 (0.58) | HTR6 | |
| SCHEMBL4488667 | 0.70 | HTR6 (0.57) | HTR6ALDH1A1L3MBTL1 | |
| SCHEMBL28128723 | 0.69 | MET (0.47) | HTR6HTR2CHTR2ASLC6A2 | |
| SCHEMBL4483744 | 0.69 | PARP1 (0.46) | HTR6ALDH1A1HTR2CHTR7HTR3A | |
| SCHEMBL27512743 | 0.69 | HTR6 (0.57) | HTR6ALDH1A1L3MBTL1DRD2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100482662-C | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2009-04-29 | — | — | CN | claimed |
| US-7259165-B2 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-08-21 | — | — | US | claimed |
| CN-1777602-A | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2006-05-24 | — | — | CN | claimed |
| US-20040167030-A1 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | claimed |
| US-7576087-B2 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| CN-100482662-C | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2009-04-29 | — | — | CN | disclosed |
| US-20080015201-A1 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-01-17 | — | — | US | disclosed |
| US-7259165-B2 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-08-21 | — | — | US | disclosed |
| CN-1777602-A | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2006-05-24 | — | — | CN | disclosed |
| US-20040167030-A1 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167030-A1 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | HTR6 1/4885ALDH1A1 1025/4885L3MBTL1 3930/4885 |
| US-20080015201-A1 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | HTR6 1/4885ALDH1A1 1229/4885L3MBTL1 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.